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Background: Cysteine proteases are potent elastolytic enzymes and together with their inhibitor, cystatin C, have been
linked with the growth of abdominal aortic aneurysms (AAAs). These enzymes and their inhibitors have previously been
studied in AAAs, but comparisons have always been made with wall from normal aorta. Atherosclerosis is a feature of
aneurysmal disease and may therefore confound comparisons with normal wall. This study compared the expression and
activity of cysteine proteases and their inhibitors in aneurysm wall with their expression in the aortic wall of patients with
aortic occlusive disease (AOD).
Methods: Aortic wall was obtained from 82 patients with AAA and 13 with AOD. Protein expression and activity of
cathepsin B, H, K, L and S, and cystatins A, B, and C were measured by enzyme-linked immunosorbent assay and specific
fluorogenic substrate assays. Matrix metalloproteinase 9 (MMP-9) activity was measured by quantitative bioimmunoas-
say in the same extracts.
Results: AAA wall had 330% more cathepsin H protein (P .007) and>30% less cystatin C (P .03) than the aortic wall
from patients with AOD. The activity of cathepsins B, H, L, and S was significantly greater in AAA than AOD (376%, [P
< .0001], 191%, [P  0.019], 223%, P  0.002, and approximately 20% [P  0.045] respectively). MMP-9 activity was
also increased in AAA compared with AOD (P<0.0001) and levels in the wall of AAA correlated positively with cathepsin
L activity (r  0.42, P<.0001) and negatively with cystatin C (r  -0.75, P<.0001).
Conclusions: The activity of four cathepsins B, H, L, and S was higher in the aneurysm wall than in aortic wall of patients
with occlusive disease. This was associated with a reduced level of cystatin C in the aneurysmal wall. Cathepsin H was the
only protein in which there was a correlation between protein level and activity, which suggests that post-translational
modifications were responsible for activation of the other cathepsins. Increased cathepsin activity may influence the
activity of MMP-9, which is thought to have an important role in aneurysm development. (J Vasc Surg 2007;46:
1260-6.)
Clinical Relevance: The incidence of abdominal aortic aneurysms has been steadily increasing for the last 3 decades. The
condition is associated with a progressive loss of structural proteins such as elastin and collagen from the wall of the aorta
through increased protease activity. Metalloproteinases have been the most predominantly studied enzymes, but there is
increasing evidence that other protease systems such as the cysteine proteases may also be involved. Controlling the
activity of proteases may form the basis for the development of novel medical treatments that inhibit aneurysm expansion
and thereby reduce the need for surgery.Abdominal aortic aneurysm (AAA) expansion is associ-
ated with loss of elastin and increased collagen degradation
in the aortic wall.1-4 Most investigations into the pathogen-
esis of aneurysm expansion have concentrated on the reg-
ulation of matrix turnover by matrix metalloproteinases
(MMP).5-8 The importance of the cysteine protease family
has received less attention, perhaps because these enzymes
were originally thought to be “redundant” lysosomal scav-
engers.
Most cathepsins are cysteine proteases with potent
elastolytic activity, although some such as cathepsin D and
E are examples of aspartic proteases. Although 11 members
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1260are known in man, only cathepsin B, H, K, L, and S, and
more recently V, have been well characterized and their
three-dimensional crystal structure identified.9 Structural
differences in each cathepsin lead to variation in their
mechanism of action.10,11
Most cathepsins are endopeptidases except cathepsin
H, which also exhibits exopeptidase activity.12 The cathe-
psins are inhibited by a number of cysteine protease inhib-
itors including cystatin A, B, and C.10,13 Cystatin A and B
are intracellular inhibitors of cathepsin activity. Cystatin C
is secreted and is therefore the major extracellular inhibitor
of these enzymes. The proteolytic activity of some cathep-
sins was found to be up to 10 times more powerful than the
MMPs.14,15 It is possible that cysteine proteases contribute
to aneurysm expansion by degrading extracellular matrix,
activating other proteases such as the MMPs, and activating
cytokines that initiate inflammatory responses.16-18
Cysteine proteases have been measured in aneurysmal
wall,19-24 but comparisons have always been made between
AAA and the normal aortic wall. Our previous work on
MMP expression in AAA indicated that the comparison
between AAA and normal aorta is potentially confounded
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elevated levels of MMP9 in the aneurysmal wall that we
found to be equally highly expressed in aortic wall from
occlusive disease. Comparing cathepsins expression in an-
eurysmal with occlusive disease removes this confounding
factor because both conditions are associated with the
presence of atherosclerosis. To our knowledge, there have
been no comparisons of the protein or activity levels of
cysteine proteases or their inhibitors (the cystatins) in an-
eurysm wall with aortic wall obtained from aortic occlusive
disease (AOD).
This study examined the differential expression (pro-
tein and activity) of five major cathepsins (B, H, K, L,
and S) and three of their main inhibitors, cystatins A, B,
and C, in aortic aneurysm wall and wall from aortic
occlusive disease. Also investigated was the relationship
between cathepsin activity and the activity of MMP9, an
enzyme that is postulated to have an important role in
aneurysm formation.25-27
METHODS
Full thickness anterior aortic wall tissue was taken (2.5
cm below renal arteries) from 82 patients who underwent
elective open AAA repair and 13 patients who underwent
aorto-distal bypass for AOD. All subjects had their surgery
at St Thomas Hospital, London, United Kingdom, be-
tween 2003 and 2005. The study was approved by the local
ethics committee (ref: EC03/098) and informed consent
was obtained from all patients. The samples were immedi-
ately collected from the operating theater and attached
mural thrombus separated from the aortic wall. The aortic
wall tissue was diced and snap-frozen in liquid nitrogen.
Samples were stored at –80° C until extraction (1 month
of collection).
Extraction for enzyme linked immunosorbent assay
measurement. Approximately 200 mg of the frozen tissue
was reduced to a powder with using a Mikro-Dismembra-
tor S (Sartorius AG, Goettingen, Germany).
For cathepsin expression and activity studies, approxi-
mately 100 mg of the tissue powder was lysed in 1 mL of
40mM sodium acetate buffer (pH 5.5) containing 1%
Triton X-100, and 1mM ethylenediaminetetraacetic acid
(EDTA). For MMP-9 activity analysis, approximately 100
mg of the powder was lysed in 1 mL of phosphate buffered
saline (pH 7.4) containing 1% Triton X-100 and 5 L of
protease inhibitor cocktail set III (Calbiochem, EMD Bio-
sciences Inc, San Diego, Calif).
The tissue lysates were centrifuged at 16000g for 20
minutes at 4°C and the supernatant collected and ali-
quoted.
Cathepsin B, H, K, L, and S protein quantification.
Specific enzyme linked immunosorbent assays were used to
measure the antigen levels of cathepsin B (R&D Systems,
Minneapolis, Minn), cathepsin K (Biomedica Gruppe,
Vienna, Austria), cathepsin L (Calbiochem), cathepsin H,
cathepsin S, cystatin A and B (KRKA,d.d, Novo Mesto,
Slovenia), and cystatin C (BioVendor GmbH, Heidelberg,
Germany) according to manufacturers’ protocols. The finalprotein values were expressed as nanograms per milligram
of soluble protein in the tissue extract.
Cathepsin B, K, L and S activity. Cathepsins B, K, L,
S activity were measured using specific fluorogenic sub-
strates labelled with 7-amino-4-trifluoromethylcoumarin
(AFC; BioVision, Mountain View, Calif). Briefly, the syn-
thetic substrates were incubated with samples in reaction
buffer for 2 hours at 37°C. Standard curves were con-
structed using free AFC (BioVision). The specificity of the
assay was confirmed by incubating samples (as a negative
control) in the presence of cathepsin-specific inhibitors
provided by the manufacturer. The released fluorescence
activity was measured using Gemini XPS fluorimeter
(Molecular Devices, Sunnyvale, Calif) at 400-nm excita-
tion filter and 505-nm emission filter. Final values were
expressed as micromoles of released AFC at 2 h/mg of
soluble protein in tissue extract.
Cathepsin H activity. The relative activity of cathep-
sin H in samples from the aortic wall tissue was determined
against the substrate H-arg-4-methylcoumarin-7-amide
(AMC; Bachem AG, Weil am Rhein, Germany), which is
specifically hydrolyzed by cathepsin H, releasing AMC
fluorescence.28 Samples were incubated with H-Arg AMC
at a final concentration of 5M. The incubation was done
in assay reaction buffer containing 100mM KH2PO4,
100mM Na2HPO4, 1mM EDTA, 1M bestatin, 2mM
cysteine, and 1mM of dithiothreitol (DTT), in pH 6.8. The
reaction was stopped after 10 minutes incubation at 37°
using 100mM sodium chloroacetate buffer containing
30mM sodium acetate and 70mM acetic acid, pH 4.3.
Standard curves were constructed using free AMC sub-
strate. The resulting fluorescence was read by Gemini XPS
fluorometer at a wavelength of 360 nm for the excitation
filter and 460 nm for the emission filter. The results were
expressed as nanomoles of AMC released at 10 min/mg of
soluble protein.
Relative cathepsin H activity was measured rather than
absolute activity. The selective inhibitor of cathepsin H
(H-Leucine-chloromethyl ketone) is rapidly destroyed by
the thiol compounds needed for the cathepsin activity
assay. It was therefore not possible to use this inhibitor in
this assay. A number of procedures were however, carried
out to ensure specificity of cathepsin H assay. The assay was
carried out at low pH of 6.8 in the presence of dithiothre-
itol (DTT), which provided an acidic and reducing envi-
ronment that is optimal for cathepsin activity. Addition of
bestatin and EDTA to the assay buffer abolished the activity
of the aminopeptidases and MMPs, respectively. Inclusion
of a serine protease inhibitor (aprotinin) and an aspartic
protease inhibitor (pepstatin A) had no effect on the per-
formance of the cathepsin H assay.
Matrix metalloproteinase 9 activity assay. Endogenous
levels of active MMP-9 were measured using a specific
activity assays (Biotrak, Amersham Biosciences, Bucking-
hamshire, UK) and expressed as picograms per milligram of
soluble protein in tissue extract.
Soluble protein content. The soluble protein content
of each tissue lysate was determined using the Coomassie
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Ill). The resulting values were used to standardize all assay
measurements against the soluble protein content of the
sample (milligrams of soluble protein).
Statistical analysis. Cathepsin and cystatin protein
levels, their activities, and activity of MMP-9 were ex-
pressed as medians with an interquartile range. Compari-
sons were made with the Mann-Whitney test. The Pearson
correlation analysis was used to study the relationship be-
tween the activity of the cathepsins and that of MMP-9
after log transformation of the skewed data. The Fisher
exact test was used to analyze demographic differences
except age when independent t test was used. Prism soft-
ware (GraphPad Prism, San Diego, Calif) was used for all
statistical analysis.
RESULTS
Patients demographics. No significant difference was
found between the two patients groups from whom the
samples were obtained in any demographic variable includ-
ing age, sex, smoking, hypertension, cardiovascular events,
and diabetes (Table I).
Protein levels cathepsins and cystatins in aneurysms
and occlusive wall. Cathepsins B, H, K, L, S and their
inhibitors cystatin A, B, C antigens were detectable in both
aneurysmal and occlusive wall. Significantly greater levels of
cathepsin H antigen were found in aneurysms (8.92
ng/mg sol protein; 5.2-15.8) compared with occlusive
aortic walls (2.7 ng/mg sol protein; 1.5-8.9; P  .007,
Table II). The level of the extracellular inhibitor, cystatin
C, was also significantly lower in aneurysmal wall (30.9
ng/mg sol protein; 17.5-44.9) compared with aortic wall
from occlusive disease (43.3ng/mg sol protein 26-53.6, P
 .03, Table II).
No significant difference was found between aneurys-
mal and occlusive aortic wall in cathepsin B, K, L, and S
protein levels or in the levels of the intracellular inhibitors,
Table I. Demographics of patients with abdominal aortic
aneurysm and aortic occlusive disease*
Characteristics†
AAA
(n  82)
AOD
(n  13) P
Mean age, y 73 (61-80) 66 (57-66) .12
Median AAA size, cm 6.7 (5.3-10) . . . . . .
Sex distribution .36
Males 73 9
Females 9 4
Smoking history 62 (76) 10 (77) 1.00
Hypertension 56 (68) 5 (39) .81
Ischemic heart disease 42 (51) 7 (54) 1.00
Diabetes 9 (11) 4 (31) .08
AAA, Abdominal aortic aneurysm; AOD, aortic occlusive disease.
*Comparisons used independent t test, with group mean and range in years.
All other comparisons were by the Fisher exact test.
†Continuous data are presented as mean (range) and categoric data as
number (%).cystatin A and B (Table II).Cathepsin activity in aortic wall. The aneurysmal
wall contained significantly higher activities of cathepsin B,
H, L, and S than the wall from AOD. Cathepsin K activity
was not significantly different between the aneurysmal and
occlusive aortic wall (Table III).
No correlation existed between the protein and activity
levels of cathepsin B, L, K and S. Cathepsin H protein
levels, did however, correlate with cathepsin H activity in
the aneurysm wall (r  0.4714, P  .0001, Fig 1).
Matrix metalloproteinase 9 activity. MMP9 activity
was greater in AAA wall (70.5 pg/mg sol protein; 50-103)
than in wall from AOD (42 pg/mg sol protein; 33-53; P
.0019, Fig 2). A strong inverse correlation was found
between the level of active MMP9 and the level of cystatin
C in AAA wall (r 0.75, P  .0001, Fig 3) and a positive
correlation with the activity of cathepsin L (r  0.42, P
value 0.0001, Fig 4). MMP9 activity was not correlated
with cathepsin activity or cystatin levels in the AOD wall.
DISCUSSION
A weakness of many studies comparing gene or protein
expression in aneurysmal tissue with tissue from nonaneu-
rysmal vessel wall is that morphologic differences, such as
the presence of atheroma in aneurysmal wall, may con-
Table II. Comparison of cathepsin and cystatin protein
levels in abdominal aortic aneurysm and aortic occlusive
disease
Protein
expression
(ng/mg sol
protein)† AAA (n  82) AOD (n  13) P*
Cathepsin B 12.3 (7.8-20) 7.9 (4-24) .45
Cathepsin H 8.9 (5.2-15.8) 2.7 (1.5-8.9) .007
Cathepsin K 12.1 (9.2-15.6) 14.8 (10.8-18.4) .17
Cathepsin L 20.3 (15.7-32.7) 22.0 (14.9-36.7) .69
Cathepsin S 4.7 (2.7-6.8) 3.7 (1.6-7.8) .74
Cystatin A 10.5 (5.7-18.3) 9.4 (4.1-20.5) .64
Cystatin B 11.1 (7.1-15.4) 12.0 (10.6-16.6) .35
Cystatin C 30.9 (17.5-44.9) 43.3 (26-53.6) .03
AAA, Abdominal aortic aneurysm; AOD, aortic occlusive disease.
*Mann-Whitney U tests.
†Values are median (interquartile range).
Table III. Comparison of cathepsin and cystatin activity
in abdominal aortic aneurysm and aortic occlusive disease
Activity* AAA (n  82) AOD (n  13) P†
Cathepsin B 31.6 (13-66.3) 8.4 (3.7-16.4) .0001
Cathepsin H 275 (152-570) 144 (78-331) .019
Cathepsin K 10.1 (6-14.2) 11.2 (6.6-15.6) .7
Cathepsin L 207 (85-629) 93 (36-141) .002
Cathepsin S 246 (117-500) 203 (37-269) .045
AAA, Abdominal aortic aneurysm; AOD, aortic occlusive disease.
*Substrate conversion/mg sol protein/unit time. Values are median (inter-
quartile range).
†Mann-Whitney U test.found the analysis. Differences in protein (or gene) expres-
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normal wall8. “Normal” aortic tissue is usually only avail-
able from organ donors. These are often young individuals,
and it is therefore difficult to match these accurately for
demographic and vascular risk factors. Comparison be-
tween AAA and AOD removes age as well as the presence of
atherosclerosis as confounding variables. To our knowl-
edge, the present study is the first to compare the expres-
sion (protein and activity) of cathepsins and their inhibitors
in aneurysmal wall with aortic wall obtained from patients
with aortic occlusive disease.
This study shows that the activities of cathepsins B, H,
L, and S are significantly higher and the levels of their main
extracellular inhibitor, cystatin C, are significantly lower in
the aneurysmal wall compared with wall from aortic occlu-
sive disease. The cathepsin protein levels, with the excep-
tion of cathepsin H, were, however, similar in both groups,
suggesting that these enzymes undergo post-translational
Fig 1. Correlation of cathepsin H protein and activity in abdom-
inal aortic aneurysm wall.
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Fig 2. Comparison of matrix metalloproteinase 9 (MMP-9) ac-
tivity in abdominal aortic aneurysm (AAA) and aortic occlusive
disease (AOD) wall. Error bars show the standard error.modification.The increased levels of cathepsin H protein and activity
found in this study appear to confirm the microarray gene
analysis that compared AAA with normal aortic wall and
showed up-regulation of the cathepsin H gene by as much
as 30-fold in AAA.29 Cathepsin H has been excluded as a
candidate gene in genetic studies of AAA in a large family
with a history of this condition, although not in sib-pairs.30
These data suggest that the higher level and activity of
cathepsin H found in AAA in the present study were the
result of translational changes.
Increased activity of the potent elastolytic cathepsin B,
H, and L and decreased levels of cystatin C, their extracel-
lular inhibitor, have previously been individually reported
Fig 3. Correlation of cystatin C levels with matrix metallopro-
teinase-9 (MMP-9) activity in abdominal aortic aneurysm wall.
Fig 4. Correlation of cathepsin L and matrix metalloproteinase-9
(MMP-9) activity in abdominal aortic aneurysm wall.in the aneurysm wall compared with samples from normal
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strated higher levels of cathepsins K and S protein in both
aneurysmal wall and atherosclerotic coronary and carotid
artery plaques compared with normal arteries.23,32 Similar
amounts of cathepsin K messenger RNA have been found
in atheroma and normal tissue,32 again, suggesting changes
at the post-translational level.
A recent report investigating cathepsin and MMP expres-
sion in human aneurysms, showed greater activity of cathep-
sins K, L, and S in the aneurysm wall but compared levels with
those in normal wall.33 Our study supports the differences
found in cathepsin L and S activity, but we found no difference
in the level of cathepsin K activity. The reason for this discrep-
ancy may have been because of the differences in the method
of measurement.
The presence of thrombus within the aneurysm sac may
lead to hypoxia within the adjacent vessel wall.34 Hypoxia is
a potent stimulus for a variety of inflammatory and remod-
elling mediators, although its effect on cathepsin expression
is equivocal. The presence of thrombus may therefore also
be a confounding factor in comparisons between these
studies.
The generally increased cathepsin activity found in the
aneurysmal wall in this study was associated with approxi-
mately 30% lower levels of cystatin C. The relationship
between low levels of cystatin C and AAA confirms data
from human and animal studies. Aneurysm expansion has
been correlated with decreased serum cystatin C concen-
trations,21 and lower serum levels of cystatin C have been
found in patients with dilated aortas compared with pa-
tients who had a normal aortic diameter.23 Analysis by
immunoblotting has revealed lower levels of cystatin C
expression in aneurysmal wall,23,33 and a polymorphism in
the gene encoding cystatin C has been associated with
increased aneurysm growth in humans.35,36 A greater de-
gree of destruction of the elastic lamina and aortic dilata-
tion has been reported in cystatin C and apolipoprotein E
(apoE) double knockout mice compared with apoE defi-
ciency alone. The lesion size of the coexisting atheroma was
not different in both groups, confirming the link between
cystatin C deficiency and AAA formation rather than ath-
erosclerosis.35
The increased amount of MMP-9 activity in AAA wall
found by bioimmunoassay in this study confirms previous
data from zymographic analysis.26 Our finding of a strong
inverse correlation between cystatin C and MMP-9 activity
is in line with recently reported data showing that both
MMP-9 and MMP-8 may degrade cystatin C.33 Cystatin C
also interacts with MMP9 directly. This prevents autolysis
of MMP-9, thereby potentiating its activity37 and possibly
reducing the amount of cystatin C available for inhibition
of the cathepsins. The cathepsins may activate MMPs
through the degradation of tissue inhibitor of metallopro-
teinases,16 whereas treatment using the pan-cathepsin in-
hibitor E64 also leads to increased MMP-9 activity.38 The
weak positive correlation between MMP9 activity and only
cathepsin L activity is difficult to explain. It may be that
cathepsin L directly activates MMP-9. This is speculative,however, because others have shown that it degrades
MMP-9.39
The relationship between these enzymes requires fur-
ther assessment in the laboratory. These data, together with
the positive correlation between MMP-9 activity and the
activity of cathepsin L found in this study, support the
hypothesis that there may be a regulatory positive feedback
loop between these protease systems and their natural
inhibitors17 that leads to an increased proteolytic environ-
ment in the aortic wall. Cysteine proteases may therefore
have an important role in the pathogenesis of aneurysmal
disease that goes beyond their direct effects on matrix
remodelling.16,17,40-43 Understanding the relationship be-
tween the MMPs and cathepsins may help to shed light on
this role.
In addition to being potent elastases, cathepsins, like
MMPs, are able to degrade a variety of extracellular matrix
proteins including fibronectin, the most ubiquitous extra-
cellular matrix protein,44 and fibrillar collagen.23 Although
cathepsins are optimally active at acidic pH (found in
lysosomes and in the pericellular space), cathepsin S, and to
a lesser extent, cathepsin K, are stable at neutral pH
range.45 These properties would therefore facilitate both a
pericellular and general proteolytic action on the vessel
wall.
The increased cathepsin B, H, L, and S activity found in
this study supports the concept that this enzyme family may
have a role in the pathogenesis of aneurysms. A more
detailed analysis of the action of these enzymes, in the
context of aortic wall expansion, is therefore warranted.
This may be particularly important for cathepsin H, because
this was the only enzyme that was assessed whose expression
and activity were upregulated in AAA. Inhibition or over-
expression of cathepsin B, H, L or S activity in a mouse model
of aneurysmal disease (such as the apoE–/–/angiotensin II
model), would help to elucidate how their activity influences
other protease systems such as the MMPs and the contribu-
tions that these enzymes make to aneurysmal development
and expansion.46,47 These studies might support an alterna-
tive strategy to the use of MMP inhibitors as means of pre-
venting aneurysm expansion.
CONCLUSION
Our study confirms that some members of the cathep-
sin family are over-expressed in the aneurysmal wall. There
appears to be a relationship between the activity of these
enzymes, their inhibitor, and MMP-9, an enzyme that is
strongly implicated in aneurysm development. Targeting
cathepsins, possibly through the upregulation of cystatin C,
might prevent both their direct destructive action on the
extracellular matrix and disrupt their relationship with
MMPs. This could lead to a novel therapy for the treatment
of aneurysmal disease.
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